Sarbecovirus

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

Thursday, July 29, 2021 - 1:00pm

BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

Key Points: 
  • BOTHELL, Wash., July 29, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.
  • Cocrystal previously announced that CDI-45205 and analogs exhibited broad-spectrum activity against the SARS-CoV-2 Alpha (United Kingdom/B.1.1.7) and Beta (South African/B.1.351) variants, surpassing the activity observed with the Wuhan strain.
  • The broad-spectrum activity against these SARS-CoV-2 variants is highly encouraging as CDI-45205 previously demonstrated excellent in vivo efficacy in a MERS-CoV-2 infected animal model.
  • The Company continues to develop SARS-CoV-2 oral protease inhibitors and replication inhibitors using its proprietary drug discovery platform technology.

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Thursday, July 29, 2021 - 1:00pm

MENLO PARK, Calif. and AUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) -- Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced positive in vitro data indicating that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.

Key Points: 
  • The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.
  • The Delta variant now accounts for 83% of new cases in the U.S., according to recent CDC data.
  • Demonstration that AUG-3387 effectively neutralizes the Delta variant in vitro is an encouraging step towards developing the therapy to slow and prevent ongoing spread of COVID-19.
  • Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially.

Global Coronavirus (COVID-19) Vaccine Market to 2026 By Infection Type, Vaccine Type, Product Type, Route of Administration, Patient Type, End User, Region - ResearchAndMarkets.com

Friday, July 30, 2021 - 11:56am

The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronavirus Vaccine Market, By Infection Type (SARS-CoV-2, SARS-CoV, MERS-CoV), By Vaccine Type, By Product Type, By Route of Administration, By Patient Type, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Vaccine Market is expected to grow at a robust rate during the forecast period.
  • The Global Coronavirus Vaccine Market is driven by the increasing prevalence of this disease across different parts of the globe.
  • The Global Coronavirus Vaccine Market is segmented based on infection type, vaccine type, product type, route of administration, patient type, end-user, company, and region.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Thursday, July 29, 2021 - 8:00pm

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Thursday, July 29, 2021 - 8:00pm

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir

Wednesday, July 28, 2021 - 1:57pm

New York, NY, and Tel Aviv, ISRAEL, July 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has retained the services of Innvocept Global Solutions, an Indian clinical research organization (CRO), to manage 2 adaptive design Phase 2/3 clinical trials the Company is preparing to initiate with its joint venture partner NLC Pharma of its proprietary oral antiviral 3CL protease inhibitor drug candidate Tollovir™ for the treatment of non-hospitalized and hospitalized COVID-19 patients in India. Engaging a CRO is the first step of the regulatory process in India.  The Company expects enrollment for both trials to begin in the third quarter of 2021 with initial, trial expansion-enabling data expected in the fourth quarter of 2021 that could make each trial become part of the Company’s global pivotal clinical development program for Tollovir that would begin in the fourth quarter of 2021.

Key Points: 
  • This trial opened enrollment in April 2021 and is also evaluating the use of TolloTest as a companion diagnostic for antiviral therapy.
  • TolloTest is the Companys proprietary 3CL protease biomarker assay that is being developed as a more accurate measure of viral infection, load and infectiousness in COVID-19 patients.
  • This dual mechanism makes Tollovir unique among the emerging class of 3CL protease inhibitors currently in development.
  • For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials.

New Publications Confirm Paragon Genomics CleanPlex® SARS-CoV-2 Panel Enables Accurate Identification of Variants of Concern

Wednesday, July 28, 2021 - 12:00pm

The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.

Key Points: 
  • The analyses enabled the researchers to assign the viral genomes to SARS-CoV-2 lineages and confirm the presence of the B.1.1.7 variant.
  • A third study, from a Paragon Genomics public health laboratory customer, describes how the CleanPlex SARS-CoV-2 Panel enabled the early identification of one of the first confirmed cases of the B.1.617.2 Delta variant in Brazil.
  • Paragon Genomics' CleanPlex SARS-CoV-2 technology has powered variant detection and tracking since the virus first appeared.
  • In March 2020, the company launched the CleanPlex SARS-CoV-2 Panel whole genome SARS-CoV-2 sequencing on Illumina and MGI Tech sequencing platforms.

Vertosa Announces U.S. Patent, Engages Emery Pharma for Research That Applies Their Pharmaceutical Development Expertise to Cannabis-Infused Products

Tuesday, July 27, 2021 - 2:00pm

Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.

Key Points: 
  • Founded in 2018, Vertosa is a science-first cannabis company that creates the most effective and reliable active ingredients for infused products.
  • The team at Emery Pharma is skilled in Method Development and Validation, Characterization and Isolation of impurities, Stability Studies, and Release Testing.
  • Emery Pharma also develops methods and procedures in support of patent litigation , intellectual property, drug recalls, and product liability cases.
  • Since March 2020, Emery Pharma has engaged in development of a Sars-CoV-2 surrogate betacoronavirus assay for antiviral efficacy testing.

VIRALEZE SPL7013 virucidal (>99.99%) against Delta variant

Tuesday, July 27, 2021 - 1:09pm

New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure

Key Points: 
  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
    SPL7013, the antiviral agent in VIRALEZE, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
    These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
    VIRALEZE antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.
  • MELBOURNE, Australia, July 27, 2021 /PRNewswire/-- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.
  • The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, atThe Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.
  • Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE) are shown in the table below.

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Tuesday, July 27, 2021 - 12:00pm

Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) today announced it has entered into a licensing agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.
  • The NRC technologies, developed with support from the NRCs Pandemic Response Challenge Program, will expedite the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical studies.
  • Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms.
  • Its lantibiotics program features a novel class of antibiotics against infectious diseases that have developed resistance to commercial antibiotics.